Fig 1.
PRISMA flowchart of included and excluded trials.
Table 1.
Characteristics of the trials included in the meta-analysis.
Table 2.
Risk of bias assessment.
Fig 2.
Network plot of included studies comparing different pharmacological strategies.
A: PONV, B:.PON, C1: POV, C2: POV excluding separate loops, D: use of rescue anti-emetics. E1: complete response, E2: complete response excluding separate loops. The nodes show a comparison of pharmacological regimens to prevent PONV and the edges show the available direct comparisons among the pharmacological regimens. The nodes and edges are weighed on the basis of the number of included patients and inverse of standard error of effect.
Fig 3.
Expected mean ranking and SUCRA values for PONV.
A. X-axis corresponds to expected mean ranking based on SUCRA (surface of under cumulative ranking curve) value, and Y-axis corresponds to SUCRA value. Fig 3B. Expected mean ranking and SUCRA values for PON. X-axis corresponds to expected mean ranking based on SUCRA (surface of under cumulative ranking curve) value, and Y-axis corresponds to SUCRA value. Fig 3C. Expected mean ranking and SUCRA values for POV. X-axis corresponds to expected mean ranking based on SUCRA (surface of under cumulative ranking curve) value, and Y-axis corresponds to SUCRA value. Fig 3D. Expected mean ranking and SUCRA values for use of rescue anti-emetics. X-axis corresponds to expected mean ranking based on SUCRA (surface of under cumulative ranking curve) value, and Y-axis corresponds to SUCRA value. Fig 3E. Expected mean ranking and SUCRA values for complete response. X-axis corresponds to expected mean ranking based on SUCRA (surface of under cumulative ranking curve) value, and Y-axis corresponds to SUCRA value.
Table 3.
League table for PONV.
Table 4.
League table for PON.
Table 5.
League table for POV.
Table 6.
League table for rescue anti-emetics.
Table 7.
League table for complete response.
Table 8.
The GRADE evidence quality for each outcome.